CURE staff

Adding Ibrance to maintenance therapy extends the time some patients with metastatic breast cancer live without their disease progressing.

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Researchers found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment.

The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma.

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric patients with T-ALL and T-LBL.

A phase 2 trial showed onvansertib plus FOLFIRI and Avastin improved response and disease control in first-line RAS-mutated metastatic colorectal cancer.

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

The NCCN Clinical Practice Guidelines in Oncology now include Besremi as a Category 1 preferred treatment option for some with high-risk essential thrombocythemia.

The FDA granted breakthrough therapy designation to bezuclastinib plus Sutent for patients with gastrointestinal stromal tumors following progression.

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

The FDA cleared a phase 3 trial of iSCIB1+ for advanced melanoma after phase 2 data showed improved progression free survival versus standard care.

Learn about large cell lung cancer, from diagnosis to stage-specific treatments, side effects and care options to guide patients through their journey.

The FDA granted fast track designation to Enolen for patients with low-to-intermediate risk prostate cancer.

FDA granted breakthrough therapy designation to zoldonrasib for previously treated KRAS G12D-mutated non-small cell lung cancer.

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with polycythemia vera.

Watch Dr. Anne O'Dea, from University of Kansas Medical Center, discuss targeting ESR1 mutations during the CURE Educated Patient® Breast Cancer Summit at MBCC.

As part of its Heal at Home series, CURE® worked with a registered dietitian from Georgetown Lombardi Comprehensive Cancer Center to put together several cancer-friendly dishes that everyone can enjoy this summer.

The vaccine immune response monitoring platform can identify weak responses in patients with cancer and help determine the potential need for a booster shot.

Although Stivarga may cause side effects after initial treatment, a dose escalation strategy and the preemptive use of steroid creams may help patients to tolerate the regimen better, while allowing them to capitalize on the agent’s survival benefit.

View the full CURE Educated Patient Breast Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

CURE will host a webinar, sponsored by Amgen, in which panelists from several cancer organizations will discuss ways to improve awareness around biomarker testing, improve coordination of care for patients with lung cancer and remove barriers to access to care.

CURE® is proud present the EDUCATED PATIENT® Gastrointestinal Stromal Tumor (GIST) Webinar from Tuesday, January 26, 2021.

A roundup of some skin cancer news and updates that occurred in 2020 that patients may have missed.

A roundup of some kidney cancer news and updates that occurred in 2020 that patients may have missed.

A roundup of some ovarian cancer news and updates that occurred in 2020 that patients may have missed.

Here are the top 10 most popular contributor articles from 2020!

A roundup of some of the most read news and updates in breast cancer in 2020 from CURE®.

A roundup of some of the most read news and updates in follicular lymphoma in 2020 from CURE®.

A roundup of some of the most read news and updates in mantle cell lymphoma in 2020 from CURE®.